Skip to main content
SpringerLink
Log in

Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development

  • Protocol
  • First Online:
Drug Safety Evaluation

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1641))

Abstract

A pediatric assessment is now a required component of every drug marketing application in North America, Europe, and Japan, unless a waiver has been granted previously. Nonclinical juvenile toxicity studies are often required as part of this assessment. The protocols for juvenile toxicity studies are best devised in consultation with the regulatory authorities. It is important to submit the pediatric investigation plan (PIP) or pediatric study plan (PSP) early, in order not to delay the marketing authorization of the drug in adults. The choice of species and the design of juvenile toxicity studies are based on a series of complex considerations, including the therapeutic use of the drug, age at which children will be treated, duration of treatment, and potential age- or species-specific differences in efficacy, pharmacokinetics, or toxicity.

To the children of the world: For their patience in waiting for the safe and effective medicines they deserve! John van den Ander [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mulberg AE, Silber SA, Van den Anker JN (2009) Pediatric drug development: concepts and applications. Wiley, Hoboken, NJ

    Google Scholar 

  2. ICH (2009) Guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf. Accessed 17 Feb 2016

  3. ICH (2000) Harmonised Tripartite Guideline: Clinical investigation of medicinal products in the pediatric population E11. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step4/E11_Guideline.pdf. Accessed 14 Jan 2016

  4. FDA (2006) Guidance for industry: nonclinical safety evaluation of pediatric drug products. FDA, Silver Spring

    Google Scholar 

  5. Shirkey H (1968) Editorial comment: therapeutic orphans. J Pediatr 72(1):119–120

    Article  CAS  PubMed  Google Scholar 

  6. Choonara I (2000) Clinical trials of medicines in children: US experience shows how to ensure that treatment of children is evidence based. Br Med J 321(7269):1093

    Article  CAS  Google Scholar 

  7. FDA (2013) FDA Voice: FDA takes step to encourage pediatric drug studies. http://blogs.fda.gov/fdavoice/index.php/tag/best-pharmaceuticals-for-children-act-bpca/. Accessed 5 Aug 2015

  8. Allegaert K, van den Anker JN (2015) Adverse drug reactions in neonates and infants: a population-tailored approach is needed. Br J Clin Pharmacol 80(4):788–795

    Article  PubMed  PubMed Central  Google Scholar 

  9. American Academy of Pediatrics Committee on Drugs (1995) Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 95(2):286–294

    Google Scholar 

  10. Nunn A, Richey R, Shah U, Barker C, Craig J, Peak M, Ford J, Turner M (2013) Estimating the requirement for manipulation of medicines to provide accurate doses for children. Eur J Hosp Pharm Sci Pract 20(1):3–7

    Article  Google Scholar 

  11. American Academy of Pediatrics Committee on Drugs (2014) Off-label use of drugs in children. Pediatrics 133(3):563–567

    Article  Google Scholar 

  12. 108th Congress S. (2003) 650 (108th): Pediatric research equity act. GovTrack.us. https://www.govtrack.us/congress/bills/108/s650. Accessed 9 Sep 2015

  13. FDA (2007) Food and drug administration amendments act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm . Accessed 03 March 2015

  14. FDA (2011) Implementation of the biologics price competition and innovation act of 2009. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm215089.htm. Accessed 16 Sep 2015

  15. European Union, Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union (2006). pp L378-1-19. 27 Dec 2006

    Google Scholar 

  16. European Union, Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use. Off J Eur Union (2006). pp L378-20-21. 27 Dec 2006

    Google Scholar 

  17. FDA (2006) Non-clinical testing in juvenile animals on human pharmaceuticals for pediatric indications. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079247.pdf. Accessed 14 Jan 2016

  18. EMA (2008) Guideline on the need for non-clinical testing in juvenile animals on human pharmaceuticals for paediatric indications. Ref. EMEA/CHMP/SWP/169215/2008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003305.pdf

  19. MHLW Japan (2012) Guideline on the nonclinical safety study in juvenile animals for pediatric drugs and questions and answers regarding guideline on the non-clinical safety study in juvenile animals for pediatric drugs

    Google Scholar 

  20. Barrow P (1990) Oral dosing of neonatal rats. In: Barrow P (ed) Technical procedures in reproduction toxicology, vol 11. Laboratory Animal Handbooks Royal Society of Medicine, London, p 49

    Google Scholar 

  21. ICH (2014) Final concept paper. S11: nonclinical safety testing in support of development of pediatric medicines. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S11/S11_Final_Concept_Paper_10_November_2014.pdf. Accessed 05 Aug 2015

  22. USNIH (2014) ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results/map?term=pediatric&recr=Open&no_unk=Y. Accessed 17 Jan 2016

  23. Shaddy RE, Denne SC (2010) The Committee on Drugs, Committee on Pediatric Research, Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 125(4):850–860

    Article  PubMed  Google Scholar 

  24. Cappon GD (2011) Nonclinical support of pediatric drug development in a global context: an industry perspective. Birth Defects Res B Dev Reprod Toxicol 92(4):269–272

    CAS  PubMed  Google Scholar 

  25. Sakiyama M (2013) Current research situation and challenges of pediatric clinical studies in Japan (Presentation). http://www.pmda.go.jp/files/000153085.pdf. Accessed 18 Sep 2015

  26. Ishikawa I (2013) PMDA’s experiences and challenges in pediatric drug development (Presentation). http://www.pmda.go.jp/files/000205934.pdf. Accessed 18 Sep 2015

  27. EMA (2015) Opinions and decisions on paediatric investigation plans. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129. Accessed 16 Sep 2015

  28. Field M, Boat T (2012) Safe and effective medicines for children: pediatric studies conducted under the best pharmaceuticals for children act and the pediatric research equity act. The National Academies Press, Washington, DC

    Google Scholar 

  29. Hurtt ME, Engel S (2015) An update of juvenile animal studies in the European Union: What do the numbers say? Reprod Toxicol 56:105–108

    Article  CAS  PubMed  Google Scholar 

  30. Baldrick P (2013) The evolution of juvenile animal testing for small and large molecules. Regul Toxicol Pharmacol 67(2):125–135

    Article  PubMed  Google Scholar 

  31. Hines RN, Sargent D, Autrup H, Birnbaum LS, Brent RL, Doerrer NG, Cohen Hubal EA, Juberg DR, Laurent C, Luebke R, Olejniczak K, Portier CJ, Slikker W (2010) Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population. Toxicol Sci 113(1):4–26

    Article  CAS  PubMed  Google Scholar 

  32. Krasinski K, Perkin R, Rutledge J (1982) Gray baby syndrome revisited. Clin Pediatr (Phila) 21(9):571–572

    Article  CAS  Google Scholar 

  33. Gershanik J, Boecler B, Ensley H, McCloskey S, George W (1982) The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 307(22):1384–1388

    Article  CAS  PubMed  Google Scholar 

  34. Allegaert K, van den Anker J (2015) Neonatal drug therapy: The first frontier of therapeutics for children. Clin Pharmacol Ther 98(3):288–297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Offringa M, Davis JM, Turner MA, Ward R, Bax R, Maldonado S, Sinha V, McCune SK, Zajicek A, Benjamin DK (2015) Applying regulatory science to develop safe and effective medicines for neonates report of the US Food and drug administration first annual neonatal scientific workshop, October 28–29, 2014. Therap Innov Regul Sci 49(5):623–631

    Article  Google Scholar 

  36. Eiby YA, Wright LL, Kalanjati VP, Miller SM, Bjorkman ST, Keates HL, Lumbers ER, Colditz PB, Lingwood BE (2013) A pig model of the preterm neonate: anthropometric and physiological characteristics. PLoS One 8(7):e68763

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bailey GP, Marien D (2011) The value of juvenile animal studies “What have we learned from preclinical juvenile toxicity studies? II”. Birth Defects Res B Dev Reprod Toxicol 92(4):273–291

    Article  CAS  PubMed  Google Scholar 

  38. Walzer M, Bekersky I, Wanaski S, Collins S, Jortner B, Patterson R, Garman R, Sagar S, Tolbert D (2011) Oral toxicity of vigabatrin in immature rats: Characterization of intramyelinic edema. Neurotoxicology 32(6):963–974

    Article  CAS  PubMed  Google Scholar 

  39. Zoetis T, Hurtt ME (2003) Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol 68(2):111–120

    Article  CAS  PubMed  Google Scholar 

  40. Walthall K, Cappon GD, Hurtt ME, Zoetis T (2005) Postnatal development of the gastrointestinal system: a species comparison. Birth Defects Res B Dev Reprod Toxicol 74(2):132–156

    Article  CAS  PubMed  Google Scholar 

  41. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118(2):250–267

    Article  CAS  PubMed  Google Scholar 

  42. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A. Clin Pharmacokinet 37(6):485–505

    Article  PubMed  Google Scholar 

  43. Morgan E, MacGeoch C, Gustafsson J (1985) Hormonal and developmental regulation of expression of the hepatic microsomal steroid 16 alpha-hydroxylase cytochrome P-450 apoprotein in the rat. J Biol Chem 260(22):11895–11898

    CAS  PubMed  Google Scholar 

  44. Johnson TN, Rostami-Hodjegan A (2011) Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatr Anesth 21(3):291–301

    Article  Google Scholar 

  45. Yang X, Morris SM, Gearhart JM, Ruark CD, Paule MG, Slikker W, Jr., Mattison DR, Vitiello B, Twaddle NC, Doerge DR, Young JF, Fisher JW (2014) Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. PLoS One 9 (9):e106101.

    Google Scholar 

  46. Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, Theogaraj E, Singer T (2011) Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet 50(9):613–623

    Article  CAS  PubMed  Google Scholar 

  47. ICH (2015) Harmonised tripartite guideline: detection of toxicity to reproduction for medicinal products & toxicity to male fertility S5(R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5/Step4/S5_R2__Guideline.pdf. Accessed 1 April 2016

  48. Silva-Lima B, Due Theilade-Thomsen M, Carleer J, Vidal JM, Tomasi P, Saint-Raymond A (2010) Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors. Birth Defects Res B Dev Reprod Toxicol 89(6):467–473

    Article  CAS  PubMed  Google Scholar 

  49. Carleer J, Karres J (2011) Juvenile animal studies and pediatric drug development: a European regulatory perspective. Birth Defects Res B Dev Reprod Toxicol 92(4):254–260

    CAS  PubMed  Google Scholar 

  50. Leconte I, Bailey G, Davis-Bruno K, Hew KW, Kim J, Silva Lima B, Liminga U, Moffit J, De Schaepdrijver L, Schmitt G, Tassinari M, Thompson K, Hurtt M (2011) Value of juvenile animal studies. Birth Defects Res B Dev Reprod Toxicol 92(4):292–303

    Article  CAS  PubMed  Google Scholar 

  51. ICH (2010) Guidance for industry: S9 nonclinical evaluation for anticancer pharmaceuticals. http://www.fda.gov/downloads/Drugs/.../Guidances/ucm085389.pdf. Accessed 17 Feb 2016

  52. Duarte DM (2015) Use of juvenile animal studies to support oncology medicine development in children. Reprod Toxicol 56:97–104

    Article  CAS  PubMed  Google Scholar 

  53. EMA (2013) European Medicines Agency decision (lisdexamfetamine). P/0321/2013. http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500160560.pdf. Accessed 30 Nov 2015

  54. Cross DM, Chmielewski G, Lewis EM, Liu L, Modesitt MS, Ripp SL, Sawaryn CM, Bowman CJ (2012) Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan. Regul Toxicol Pharmacol 63(1):29–39

    Article  CAS  PubMed  Google Scholar 

  55. Schmitt G (2015) Safety of excipients in pediatric formulations—a call for toxicity studies in juvenile animals? Children 2(2):191–197

    Article  PubMed  PubMed Central  Google Scholar 

  56. EMA (2013) Guideline on pharmaceutical development of medicines for paediatric use. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf. Accessed 13 Aug 2015

  57. EMA (2006) Reflection paper: formulations of choice for the paediatric population. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf. Accessed 30 Nov 2015

  58. EuPFi (2015) STEP database. http://pharmacyapp-a.ucl.ac.uk:8080/eupfi. Accessed 13 Aug 2015

  59. Morford LL, Bowman CJ, Blanset DL, Bøgh IB, Chellman GJ, Halpern WG, Weinbauer GF, Coogan TP (2011) Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices. Birth Defects Res B Dev Reprod Toxicol 92(4):359–380

    CAS  PubMed  Google Scholar 

  60. Weinbauer GF, Luft J, Fuchs A (2013) The enhanced pre- and postnatal development study for monoclonal antibodies. Methods Mol Biol 947:185–200. m

    Article  CAS  PubMed  Google Scholar 

  61. Sakurai T, Takai R, Buergin H, Shioda A, Sakamoto Y, Amano J, Grimm HP, Richter WF, Higuchi Y, Chiba S (2013) The effects of interleukin-6 signal blockade on immune system, reproductive and skeletal development in juvenile mice. Birth Defects Res B Dev Reprod Toxicol 98(2):170–182

    Article  CAS  PubMed  Google Scholar 

  62. ICH (2011) Harmonised tripartite guideline: preclinical safety evaluation of biotechnology-derived pharmaceuticals. S6(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf. Accessed 17 Feb 2016

  63. Guay-Woodford LM, Bryda EC, Lindsay JR, Avner ED, Flaherty L (1996) The mouse bpk mutation, a model of autosomal recessive polycystic kidney disease (ARPKD) and jcpk: a phenotypically distinct PKD mutation, are allelic. Pediatr Res 39:361–361

    Article  Google Scholar 

  64. Hurtt ME, Sandler JD (2003) Comparative organ system development: introduction. Birth Defects Res B Dev Reprod Toxicol 68(2):85–85

    Article  CAS  PubMed  Google Scholar 

  65. Beckman DA, Feuston M (2003) Landmarks in the development of the female reproductive system. Birth Defects Res B Dev Reprod Toxicol 68(2):137–143

    Article  CAS  PubMed  Google Scholar 

  66. Hew KW, Keller KA (2003) Postnatal anatomical and functional development of the heart: a species comparison. Birth Defects Res B Dev Reprod Toxicol 68(4):309–320

    Article  CAS  PubMed  Google Scholar 

  67. Holsapple MP, West LJ, Landreth KS (2003) Species comparison of anatomical and functional immune system development. Birth Defects Res B Dev Reprod Toxicol 68(4):321–334

    Article  CAS  PubMed  Google Scholar 

  68. Marty MS, Chapin RE, Parks LG, Thorsrud BA (2003) Development and maturation of the male reproductive system. Birth Defects Res B Dev Reprod Toxicol 68(2):125–136

    Article  CAS  PubMed  Google Scholar 

  69. Watson RE, DeSesso JM, Hurtt ME, Cappon GD (2006) Postnatal growth and morphological development of the brain: a species comparison. Birth Defects Res B Dev Reprod Toxicol 77(5):471–484

    Article  CAS  PubMed  Google Scholar 

  70. Wood SL, Beyer BK, Cappon GD (2003) Species comparison of postnatal CNS development: functional measures. Birth Defects Res B Dev Reprod Toxicol 68(5):391–407

    Article  CAS  PubMed  Google Scholar 

  71. Zoetis T, Tassinari MS, Bagi C, Walthall K, Hurtt ME (2003) Species comparison of postnatal bone growth and development. Birth Defects Res B Dev Reprod Toxicol 68(2):86–110

    Article  CAS  PubMed  Google Scholar 

  72. Zoetis T, Hurtt ME (2003) Species comparison of lung development. Birth Defects Res B Dev Reprod Toxicol 68(2):121–124

    Article  CAS  PubMed  Google Scholar 

  73. Landrigan PJ, Kimmel CA, Correa A, Eskenazi B (2004) Children’s health and the environment: public health issues and challenges for risk assessment. Environ Health Perspect 112(2):257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Schlumpf M, Bütikofer E, Schreiber A, Parmar R, Ramseier H, Lichtensteiger W (1994) Delayed developmental immunotoxicity of prenatal benzodiazepines. Toxicol In Vitro 8(5):1061–1065

    Article  CAS  PubMed  Google Scholar 

  75. Barrow P (2012) Use of the swine pediatric model. In: Hoberman A, Lewis E (eds) Pediatric nonclinical drug testing. Wiley, Hoboken, NJ, pp 213–229. doi:10.1002/9781118168226.ch11

    Chapter  Google Scholar 

  76. Robinson K, Smith SY, Viau A (2012) Dog juvenile toxicity. In: Hoberman A, Lewis E (eds) Pediatric nonclinical drug testing: principles, requirements, and practices. Wiley, Hoboken, NJ, pp 183–212

    Chapter  Google Scholar 

  77. Weinbauer GF, Chellman GJ, Rasmussen AD, Vogelwedde E (2012) Use of primate pediatric model. In: Hoberman A, Lewis E (eds) Pediatric nonclinical drug testing: principles, requirements, and practices. Wiley, Hoboken, NJ, pp 255–279

    Chapter  Google Scholar 

  78. Himmel HM (2008) Safety pharmacology assessment of central nervous system function in juvenile and adult rats: Effects of pharmacological reference compounds. J Pharmacol Toxicol Methods 58(2):129–146

    Article  CAS  PubMed  Google Scholar 

  79. Lewin G, Hoymann HG, Fuhst R, Berger-Preiss E, Pohlmann G, Buschmann J (2010) Assessment of pulmonary function and serum substance levels in newborn and juvenile rats. Reprod Toxicol 30(3):422–428

    Article  CAS  PubMed  Google Scholar 

  80. Beck MJ, Padgett EL, Bowman CJ, Wilson DT, Kaufman LE, Varsho BJ, Stump DG, Nemec MD, Holson JF (2006) Nonclinical juvenile toxicity testing. In: Hood RD (ed) Developmental and reproductive toxicology: a practical approach, 2nd edn. CRC, Boca Raton, pp 263–328

    Google Scholar 

  81. Parker RM (2014) Juvenile Toxicology. In: Derelanko MJ, Auletta CS (eds) Handbook of toxicology, 3rd edn. CRC, Boca Raton, pp 400–452

    Google Scholar 

  82. Barrow P, Allais L (2013) Developmental toxicity testing of vaccines. Methods Mol Biol 947:81–89

    Article  CAS  PubMed  Google Scholar 

  83. Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, Kiialainen A, Koulov A, Boll B, Weiser T (2015) The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res:1–16

    Google Scholar 

  84. Laffan S, Posobiec L (2012) Approaches to rat juvenile toxicity studies and case studies: a pharmaceutical perspective. In: Hoberman AM (ed) Pediatric non-clinical drug testing Principles, requirements and practices. Wiley, Hoboken, NJ, pp 281–301

    Chapter  Google Scholar 

  85. Gad SC (1998) Statistics and experimental design for toxicologists, 3rd edn. CRC, Boca Raton

    Google Scholar 

  86. Zoetis T, Walls I (2003) A report of the ILSI risk science institute expert working group on direct dosing of pre-weaning mammals in toxicity testing. International Life Sciences Institute, Washington, DC

    Google Scholar 

  87. Hoberman AM, Barnett JF (2012) Juvenile toxicity study design for the rodent and rabbit. In: Hoberman A, Lewis E (eds) Pediatric nonclinical drug testing: principles, requirements, and practices. Wiley, Hoboken, NJ, pp 141–182

    Chapter  Google Scholar 

  88. Barrow P (2000) Reproductive and developmental toxicology safety studies. In: Krinke GJ (ed) The laboratory rat. Academic, London, pp 199–225

    Chapter  Google Scholar 

  89. Jonsson O, Villar RP, Nilsson LB, Norsten-Höög C, Brogren J, Eriksson M, Königsson K, Samuelsson A (2012) Capillary microsampling of 25 μl blood for the determination of toxicokinetic parameters in regulatory studies in animals. Bioanalysis 4(6):661–674

    Article  CAS  PubMed  Google Scholar 

  90. Nilsson LB, Ahnoff M, Jonsson O (2013) Capillary microsampling in the regulatory environment: Validation and use of bioanalytical capillary microsampling methods. Bioanalysis 5(6):731–738

    Article  CAS  PubMed  Google Scholar 

  91. NC3Rs Blood Sampling/Pig/Ear vein. http://www.nc3rs.org.uk/pig-ear-vein-non-surgical. Accessed 25 Aug 2015

  92. Sewald K, Mueller M, Buschmann J, Hansen T, Lewin G (2015) Development of hematological and immunological characteristics in neonatal rats. Reprod Toxicol 56:109–117

    Article  CAS  PubMed  Google Scholar 

  93. Meyer J (1998) Behavioral assessment in developmental neurotoxicology: approaches involving unconditioned behaviors and pharmacologic challenges in rodents. In: Slikker W, Chang LW (eds) Handbook of developmental neurotoxicology. Academic, New York, pp 403–426

    Google Scholar 

  94. Haagensen AM, Grand N, Klastrup S, Skytte C, Sørensen DB (2013) Spatial discrimination and visual discrimination: two methods evaluating learning and memory in juvenile göttingen minipigs. Behav Pharmacol 24(3):172–179

    Article  PubMed  Google Scholar 

  95. Bolon B, Garman RH, Pardo ID, Jensen K, Sills RC, Roulois A, Radovsky A, Bradley A, Andrews-Jones L, Butt M (2013) STP position paper recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies. Toxicol Pathol 41(7):1028–1048

    Article  PubMed  Google Scholar 

  96. Allais L, Condevaux F, Fant P, Barrow P (2009) Juvenile toxicity of cyclosporin in the rat. Reprod Toxicol 28(2):230–238

    Article  CAS  PubMed  Google Scholar 

  97. Barrow P, Ravel G (2005) Immune assessments in developmental and juvenile toxicology: practical considerations for the regulatory safety testing of pharmaceuticals. Regul Toxicol Pharmacol 43(1):35–44

    Article  CAS  PubMed  Google Scholar 

  98. Barrow P (2007) Toxicology testing for products intended for pediatric populations. Nonclinical drug safety assessment: practical considerations for successful registration. FDA News, Washington, DC, pp 411–440

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070, Basel, Switzerland

    Paul C. Barrow & Georg Schmitt

Authors
  1. Paul C. Barrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georg Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul C. Barrow .

Editor information

Editors and Affiliations

  1. Preclinical Safety, Sanofi, R&D, Vitry-sur-Seine, France

    Jean-Charles Gautier

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Barrow, P.C., Schmitt, G. (2017). Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development. In: Gautier, JC. (eds) Drug Safety Evaluation. Methods in Molecular Biology, vol 1641. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7172-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7172-5_2

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7170-1

  • Online ISBN: 978-1-4939-7172-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation